Intuniv (guanfacine XR) / Shionogi, Takeda 
Welcome,         Profile    Billing    Logout  
 14 Diseases   10 Trials   10 Trials   201 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuniv (guanfacine XR) / Shionogi, Takeda
NCT01681264: Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

Active, not recruiting
4
200
US
Morphine, MS Contin, Guanfacine 1mg, Intuniv, Tenex, Guanfacine 2mg, Placebo, Sugar Pill
Massachusetts General Hospital, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Chronic Pain
12/22
12/23
PWS-GXR, NCT05657860: Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Completed
4
15
US
Guanfacine Extended Release, Intuniv, Placebo
Maimonides Medical Center
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
12/23
12/23
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
NorAD, NCT03116126 / 2016-002598-36: Noradrenergic Add-on Therapy With Guanfacine

Active, not recruiting
3
148
Europe
Guanfacine, Placebo
Imperial College London
Alzheimer Disease
08/24
08/24
NCT04198116: Combining Varenicline and Guanfacine for Smoking Cessation

Recruiting
2
140
US
Varenicline, Chantix, Guanfacine ER, Intuniv
Yale University, National Institute on Drug Abuse (NIDA)
Smoking Cessation
07/26
07/26
NCT06629259: Guanfacine for Alcohol Use Disorder (AUD)

Not yet recruiting
2
200
US
Guanfacine Extended Release (XR), Intuniv, Placebo
Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
08/29
09/29
NCT03764098: Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

Recruiting
2
160
US
Guanfacine ER, Intuniv, Placebo
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use
02/25
02/26
NCT05273567: A Trial of Guanfacine-er for Cannabis Use Disorder

Active, not recruiting
2
90
US
guanfacine-ER, Intuniv-er, Placebo
New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA)
Cannabis Use
03/25
03/25
GRACE, NCT05957848: Guanfacine Extended-release for Adolescents With Cannabis Use

Recruiting
2
100
RoW
Guanfacine Extended Release Oral Tablet, Intuniv, Guanfacine XR, Residential withdrawal, Engagement with alcohol and other drug services, Placebo
Orygen, Youth Support and Advocacy Service, University of Melbourne
Cannabis Use Disorder
12/25
06/26
ADAPT, NCT02136147: ADHD Medication and Predictors of Treatment Outcome

Completed
N/A
632
Europe
methylphenidate medication, N06BA04, Concerta, Ritalin, Equasym, Medikinet, atomoxetine medication, N06BA09, Strattera, lisdexamphetamine medication, N06BA12, Elvanse, guanfacine medication, C02AC02, Intuniv
Karolinska Institutet
Attention Deficit Disorder With Hyperactivity (ADHD)
07/21
06/22
NCT05870605: Drug Use Study With Intuniv® in European Countries

Completed
N/A
5000
Europe
No Intervention
Shire
Attention Deficit Hyperactivity Disorder (ADHD)
04/22
04/22
NCT02192398: Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

Active, not recruiting
N/A
120
US
Guanfacine, Tenex, Intuniv, Placebo, Placebo, sugar pill
Massachusetts General Hospital, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Chronic Pain
12/22
12/24
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Active, not recruiting
N/A
20
Europe
Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo
King's College London, Shire
ADHD
12/22
03/25

Download Options